Lineage Cell Therapeutics (LCTX) Intangibles (2010 - 2026)

Lineage Cell Therapeutics has reported Intangibles for 17 years, with the latest figure at $31.7 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles changed N/A year-over-year to $31.7 million; the trailing twelve-month figure through Mar 2026 stood at $31.7 million (changed N/A YoY), and the FY2025 full-year result was $31.7 million, changed N/A from the prior year.
• Intangibles for Q1 2026 stood at $31.7 million, roughly flat from $31.7 million in the prior quarter.
• The five-year high for Intangibles was $66.1 million in Q4 2022, with the low at $31.7 million in Q2 2025.
• Historically, Intangibles has averaged $49.0 million across 5 years, with a median of $46.5 million in 2022.
• Annual changes were most pronounced in 2022 — Intangibles jumped 213.34% — and 2025, when it plunged 52.07%.
• Lineage Cell Therapeutics' Intangibles stood at $66.1 million in 2022, then retreated by 29.64% to $46.5 million in 2023, then surged by 42.12% to $66.1 million in 2024, then sank by 52.07% to $31.7 million in 2025, then changed by 0.0% to $31.7 million in 2026.
• The last three Intangibles figures came in at $31.7 million (Q1 2026), $31.7 million (Q4 2025), and $31.7 million (Q2 2025), per Business Quant data.